Xbrane Biopharma AB Sustainability Profile
Xbrane Biopharma AB, a pioneering biotechnology company headquartered in Sweden, focuses on the development of innovative biosimilars and biologics. Founded in 2006, Xbrane has made significant strides in the biopharmaceutical industry, particularly in the fields of ophthalmology and oncology. The company is renowned for its flagship product, Xlucane, a biosimilar to Lucentis, which addresses serious eye diseases and showcases Xbrane's commitment to enhancing patient care through affordable treatment options. With a strong presence in Europe and expanding operations globally, Xbrane Biopharma has established itself as a key player in the biosimilar market, recognised for its rigorous development processes and high-quality standards. As Xbrane continues to advance its pipeline, it remains dedicated to delivering innovative solutions that meet the evolving needs of healthcare providers and patients alike.
DitchCarbon Score
How does Xbrane Biopharma AB's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Xbrane Biopharma AB's score of 37 is higher than 57% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Xbrane Biopharma AB's reported carbon emissions
In 2023, Xbrane Biopharma AB reported total carbon emissions of approximately 9,000 kg CO2e, with 8,000 kg CO2e attributed to Scope 2 emissions. The company has set ambitious climate commitments, aiming to reduce its Scope 1 emissions to near zero by 2025. Additionally, Xbrane plans to cut its Scope 2 emissions by 50% from a 2020 baseline by 2030, with a target to achieve near-zero Scope 2 emissions by 2025. These initiatives reflect Xbrane's commitment to sustainability and align with industry standards for climate action.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2022 | 2023 | |
|---|---|---|
| Scope 1 | - | - |
| Scope 2 | 10,000 | 0,000 |
| Scope 3 | - | - |
How Carbon Intensive is Xbrane Biopharma AB's Industry?
How Carbon Intensive is Xbrane Biopharma AB's Location?
Xbrane Biopharma AB's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Xbrane Biopharma AB has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
